Logo
x

Search

Subscribe Now

Maintenance Therapy

Zai Lab's Zejula (niraparib) Receives NMPA's Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

Zai Lab's Zejula (niraparib) Receives NMPA's Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

  • December 30, 2019
AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive NMPA's Approval as 1L Maintenance Therapy for BRCA-Mutated Advanced Ovarian Canc...

  • December 5, 2019
Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

Celgene Reports Results of CC-486 in P-III QUAZAR AML-001 Study as Maintenance Therapy for Acute Myeloid Leukemia

  • September 13, 2019
AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer

AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advance...

  • August 29, 2019
AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer

AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer

  • August 14, 2019
Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly

Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL Study as a Maintenance Therapy for Acromegaly

  • July 23, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.